57
Participants
Start Date
March 14, 2024
Primary Completion Date
July 1, 2026
Study Completion Date
December 1, 2026
Radiotherapy
Interventions consist of 50-60 Gy in 25-30 fractions of radiotherapy.
Programmed Cell Death Protein 1 Inhibitor
200 mg of Sintilimab administered every three weeks concurrently with radiotherapy and after radiotherapy as consolidation therapy up to 1year.
Immunonutrition support
600-1600 ml of TPF-T per day according to the nutrition status evaluation
Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing
Taizhou hospital of Wenzhou Medical University, Taizhou
Department of Radiation Oncology，Clinical Oncology School of Fujian Medical University，Fujian Cancer Hospital, Fujian
Department of Oncology, Affiliated Hospital, Hebei University of Engineering, Handan
Department 1st of Radiation Oncology, Anyang Tumor Hospital, Anyang
Department of Radiation Oncology the first affiliated hospital of Xinxiang Medical University, Xinxiang
Department of Radiation Oncology, General Hospital of Ningxia Medical University, Yinchuan
Department of Radiation Oncology，Fei County People's Hospital, Feixian
Department of Radiation Oncology, Affiliated hospital of Jining Medical University, Jining
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OTHER